Navigation Links
Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
Date:4/2/2008

MACCLESFIELD, England, April 2 /PRNewswire-FirstCall/ -- Today, (2nd April 2008), Cyprotex announces that it is introducing a new product line, Cloe(R) Select. Cloe(R) Select is a portfolio of bespoke studies which can be customised to individual customer requirements. It complements the current range of Cloe(R) Screen assays to provide ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic solutions from early discovery through to later stage development projects. As with Cloe(R) Screen, Cloe(R) Select meets the criteria set by the regulatory guidelines to provide constant confidence in the quality of the data.

The drug discovery and development process represents a number of pre-clinical phases which cover hit to lead, lead optimization and candidate selection. Cyprotex can now offer a fully integrated solution in the area of ADME and pharmacokinetics throughout this entire process. We have gained extensive knowledge in our field over the past 9 years, which is attributed to investing in high caliber committed scientists and by working with a large and diverse customer base.

Mr. Robert Atwater, Cyprotex's Chief Executive Officer, comments on the launch of this new product line. "Many of our customers rely on us for their ADME projects right from early screening projects through to IND submission. Building these relationships and ensuring that we can offer a flexible and broad range of screening options has been critical in the success of our business."

Cyprotex is a specialist provider of ADME data and pharmacokinetic predictive services. Our unique Cloe(R) Screen technology which couples robust protocols with state-of-the-art automation enables Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround. Introducing Cloe(R) Select ensures that Cyprotex can extend their offering to later stage more in-depth studies which require a more flexible approach. Cyprotex also has extensive expertise in physiologically based pharmacokinetic (PB-PK) modelling and quantitative structure activity relationship (QSAR) modelling techniques under its Cloe(R) Predict service. In combination, Cloe(R) Screen, Cloe(R) Select and Cloe(R) Predict offer an integrated solution for both experimental screening and prediction, fulfilling the needs of our broad and varied customer base.

For further information:

Cyprotex PLC,

Helen Gill PhD, Product Development Manager,

Tel: +44-1625-505-100,

h.gill@cyprotex.com.

http://www.cyprotex.com


'/>"/>
SOURCE Cyprotex Discovery Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
2. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
3. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
4. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
5. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
6. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
7. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
8. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery
11. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... within the healthcare and technology sector at their fourth annual Conference where founders, ... 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital health ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):